Pharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments

MARY JEANNE KREEK, GAVIN BART, CHARLES LILLY, K. STEVEN LAFORGE, AND DAVID A. NIELSEN

The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, New York

Abstract .................................................................................. 2
I. Introduction .............................................................................. 2
II. Addictions ................................................................................ 3
A. Opiates and other opioids ............................................................... 3
1. Heroin ............................................................................. 3
2. Codeine ............................................................................ 3
3. Noncodeine prescription opioids ...................................................... 3
B. Cocaine ............................................................................... 4
III. Molecular genetics of opioid and cocaine addictions ........................................... 4
A. Epidemiology .......................................................................... 4
B. Molecular genetic studies ............................................................... 5
1. Family and linkage studies .......................................................... 5
2. Case control-association studies ...................................................... 6
3. Haplotype analysis .................................................................. 6
C. Selected identified genes ............................................................... 7
1. Opioid-related genes ................................................................ 7
a. μ opioid receptor gene (OPRM1) ................................................... 7
b. κ opioid receptor gene (OPRK1) ................................................. 11
c. δ opioid receptor gene (OPRD1) .................................................. 12
d. Preproenkephalin gene (PENK) ................................................. 12
e. Preprodynorphin gene (PDYN) ................................................. 12
2. Monoaminergic-related genes ....................................................... 13
a. Dopamine β-hydroxylase gene (DBH) ............................................. 14
b. Dopamine receptor D2 gene (DRD2) ............................................. 15
c. Dopamine transporter gene (SLC6A3) ........................................... 15
d. Serotonin transporter gene (SLC6A4) ........................................... 16
e. Norepinephrine transporter gene (SLC6A2) .................................... 16
IV. Treatment of addictions .................................................................. 17
A. Pharmacotherapies ................................................................... 17
1. Opiate and opioid addictions ........................................................ 17
a. Methadone ..................................................................... 17
b. Levo-α-acetylmethadol ................................................................. 17
c. Buprenorphine .................................................................. 18
d. Naltrexone ..................................................................... 18
e. Clonidine ...................................................................... 18
2. Cocaine addiction .................................................................. 18
a. Antidepressants ................................................................ 18
b. Disulfiram ..................................................................... 18
c. Dopaminergic agents .............................................................. 18
d. GABA A-GABA B directed drugs ................................................... 18
V. Pharmacogenetics related to the treatment of addictions ..................................... 19
A. Metabolism/biotransformation of opiates and other opioids ......................... 19

Address correspondence to: Dr. Mary Jeanne Kreek, The Rockefeller University, Box 171, 1230 York Avenue, New York, New York 10021.
E-mail: kreek@rockefeller.edu
Article, publication date, and citation information can be found at http://pharmrev.aspetjournals.org.
doi:10.1124/pr.57.1.1.
Abstract—Opiate and cocaine addictions are major social and medical problems that impose a significant burden on society. Despite the size and scope of these problems, there are few effective treatments for these addictions. Methadone maintenance is an effective and most widely used treatment for opiate addiction, allowing normalization of many physiological abnormalities caused by chronic use of short-acting opiates. There are no pharmacological treatments for cocaine addiction. Epidemiological, linkage, and association studies have demonstrated a significant contribution of genetic factors to the addictive diseases. This article reviews the molecular genetics and pharmacogenetics of opiate and cocaine addictions, focusing primarily on genes of the opioid and monoaminergic systems that have been associated with or have evidence for linkage to opiate or cocaine addiction.

I. Introduction

Opiate and cocaine addictions are chronic relapsing diseases with complex etiologies, significant comorbidities (e.g., human immunodeficiency virus, hepatitis B and C infections, depressive and anxiety disorders, and other psychiatric illnesses), and major negative socioeconomic consequences. Opiate addicts frequently suffer from cocaine addiction, and cocaine addicts frequently have comorbid alcohol addiction. There is also significant comorbid nicotine addiction in both groups. In addition, opiate and cocaine addicts often abuse marijuana and benzodiazepines. As with other complex chronic diseases such as hypertension, coronary artery disease, type 2 diabetes mellitus, and unipolar depression, the addictions develop through the interaction of various social-behavioral, physiological, and genetic factors. Because the development of the addictive diseases is predicated on the exposure to a drug of abuse, pharmacological and pharmacogenetic factors must be considered and, for opiate and cocaine addictions, will be the focus of this review.

The addictive diseases are clinically defined through a combination of physiological and behavioral criteria. Currently, the most widely used diagnostic criteria for the addictive diseases are those of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders, Third Edition—Revised; MOR, μ opioid receptor; KOR, κ opioid receptor; SNP, single nucleotide polymorphism; DOR, δ opioid receptor; HPA, hypothalamic-pituitary-adrenal; LAAM, levo-α-acetylmethadol; PET, positron emission tomography; M6G, morphine-6-glucuronide; CREB, cAMP response element-binding protein; CSF, cerebrospinal fluid; RFLP, restriction fragment length polymorphism; VNTR, variable nucleotide tandem repeat; P450, cytochrome P-450; 6-MAM, 6-monoacetylmorphine; hCE, human carboxylesterase; M3G, morphine-3-glucuronide; UGT, UDP glucuronosyltransferase.

This evidence has been marshaled either through identification of variant alleles that lead to functional alterations of gene products, altered gene expression, or findings of linkage or association studies. Studies of polymorphisms in the μ opioid receptor gene, which encodes the receptor target of some endogenous opioids, heroin, morphine, and synthetic opioids, have contributed substantially to knowledge of genetic influences on opiate and cocaine addiction. Other genes of the endogenous opioid and monoaminergic systems, particularly genes encoding dopamine β-hydroxylase, and the dopamine, serotonin, and norepinephrine transporters have also been implicated. Variants in genes encoding proteins involved in metabolism or biotransformation of drugs of abuse and also of treatment agents are reviewed.
for increased amount of substance to achieve the desired effect or diminished effect with continued use of the same amount of the substance; 2) development of a characteristic withdrawal syndrome when the substance is stopped or the use of the substance to prevent the onset of withdrawal; 3) increased or prolonged use; 4) a desire or unsuccessful attempts to cut down or control use; 5) significant time spent in activities related to drug procurement, use, and recovery; 6) important social, occupational, or recreational activities are sacrificed because of substance use; and 7) ongoing use despite knowledge of ongoing physical or psychological harm related to substance use. This is in contrast to the initial, and current, federal criteria for entrance into methadone maintenance treatment for opiate addiction (Rettig and Yarmolinsky, 1995; Kreek and Vocci, 2002). The federal criteria, which require greater than 1 year of multiple daily opiate self-administrations, far exceed the DSM-IV criteria for opioid dependence in that tolerance and withdrawal may develop within several weeks following regular opiate use.

By contrast, the DSM-IV criteria for substance abuse do not include the physiological effects of repeated drug use. Rather, a diagnosis of substance abuse is met if one or more of the following result in clinically significant impairment or distress during a 12-month period: 1) substance use results in failure to fulfill major work, school, or home obligations; 2) recurrent substance use in hazardous situations; 3) recurrent substance-related legal problems; and 4) continued use despite persistent or recurrent social or interpersonal problems related to substance use.

Although the DSM-IV refers to “substance dependence”, this causes confusion in nomenclature since frequently encountered, medically expected and accepted dependencies occur with chronically administered therapeutic agents such as all opioid analgesics, adrenocorticosteroids, and several antihypertensives. Throughout this review we will use the term “addiction” rather than “dependence” since it better describes the maladaptive and harmful aspects of persistent compulsive drug use.

II. Addictions

Whereas opiates and cocaine are discussed in this review, all drugs of abuse share a common characteristic which underlies their abuse potential: initial use in the mode and pattern of abuse leads to rapid increase or decrease of receptor and/or transporter function, neurotransmitter/neuropeptide activity, and secondary messenger signaling. Changes in the gene expression of target proteins follow frequent, repeated exposure. Cessation of drug use leads to similarly profound changes. Thus, recurrent “on-off” use of short-acting drugs produces long-term, perhaps permanent, alterations in these affected neuronal systems and underlies the development of tolerance, dependence, withdrawal, and relapse characteristic of the addictive diseases.

A. Opiates and Other Opioids

Opiates are the drugs derived from opium and include morphine, codeine, their congeners (e.g., heroin and oxycodone), and other semisynthetic derivatives of thebaine. Opioids, however, consist of all agonist drugs with morphine-like activity whether they are naturally occurring or synthetic. For the purposes of this review, opiates and opioids are discussed together. The initial effects of opiates are mediated through the endogenous opioid system. Although there are three classes of opioid receptors (μ, δ, and κ), abused opiates primarily interact with μ opioid receptors (MOR). This seven transmembrane G protein-coupled receptor modulates diverse physiological systems including response to pain and reward, stress responsivity, gastrointestinal motility, and immune function. The endogenous ligands for MOR are the 31-amino acid protein β-endorphin and the smaller enkephalin molecules. By inhibiting γ-aminobutyric acid (GABAergic) neurons, stimulation of MOR also results in disinhibition of mesolimbic-mesocortical dopamine pathways central to the reinforcing properties of opiates and other drugs of abuse. Repeated administration of and withdrawal from opiates disrupts these pathways and results in the physiological and behavioral effects of opiate addiction.

1. Heroin. The 2002 National Survey on Drug Use and Health estimated that in 2002, 19.5 million Americans age 12 or older were illicit drug users (Substance Abuse and Mental Health Services Administration, 2003b). Over 3.5 million Americans have used heroin and there are over 1 million heroin addicts in the United States. From 1995 to 2002, the prevalence of lifetime heroin use has increased among youths aged 12 to 25 with greater than 100,000 heroin initiates annually during this period.

2. Codeine. Codeine is an orally administered prescription opiate rarely administered as a sole agent. Codeine is frequently prepared in combination with decongestants and expectorants as a cough remedy and nonopiate analgesics such as acetaminophen for the treatment of pain. Although codeine itself is modestly potent, it is, in part, metabolized into the potent and reinforcing opiate morphine. Recent trends indicate that there has been a decline in the illicit use of codeine (Substance Abuse and Mental Health Services Administration, 2003b). Rather than a sign of decreased demand for prescription opiates, this decrease seems to be offset by increased illicit use of more potent prescription opioids.

3. Noncodeine Prescription Opioids. The prevalence of illicitly used codeine- and noncodeine-containing prescription opioids has been difficult to determine. An estimated 1.9 million Americans used oxycodone illicitly in 2002 (Substance Abuse and Mental Health Services...
Administration, 2003b). According to the Drug Abuse Warning Network, from 1995 to 2002 emergency room mentions of illicitly used prescription opiates increased 116% (2775 mentions in 2002) for morphine-containing analgesics, 560% (22,397 mentions in 2002) for oxycodone-containing analgesics, to over 6000% (1506 mentions in 2002) for fentanyl-containing analgesics (Substance Abuse and Mental Health Services Administration, 2003a).

B. Cocaine

Cocaine primarily acts through inhibition of presynaptic dopamine transporters as well as the serotonin and norepinephrine transporters. Increased levels of synaptic dopamine and, thereby, dopamine receptor binding following cocaine administration is a key mechanism through which cocaine is reinforcing. Cocaine also modulates the endogenous opioid system, especially MOR, κ opioid receptors (KOR), and preprodynorphin. Whereas stimulation of dopaminergic pathways may be sufficient to cause the reinforcing effects of cocaine, dopamine transporter gene deletion studies have shown that this pathway is not essential to the development of cocaine self-administration (see below). Selective gene disruption of the MOR will, however, prevent the development of cocaine self-administration (see below).

Close to 34 million Americans have used cocaine and there are over 1.5 million cocaine addicts in the United States (Substance Abuse and Mental Health Services Administration, 2003b). Discussion of other stimulant drugs such as methamphetamine and 3,4-methylenedioxy-methamphetamine (or ecstasy) as well as illicitly used prescription stimulants is beyond the scope of this review.

III. Molecular Genetics of Opioid and Cocaine Addictions

The human genome contains approximately 25–40,000 genes encoded in 3.2 billion nucleotides of DNA (Lander et al., 2001; Venter et al., 2001). It has been predicted that any two genomes, when compared, are nearly 99.9% identical (Kruglyak and Nickerson, 2001). A substantial portion of the 0.1% genetic variability between individuals is due to the 11 million single nucleotide polymorphisms (SNPs) estimated to occur in the human genome with allelic frequencies greater than 1% (Kruglyak and Nickerson, 2001). Variability is also introduced by such processes as alternative splicing of mRNA transcripts and imprinting.

Polymorphisms (or variants) in genes, which code for proteins that are in the pathways where heroin or cocaine act, especially when their expression results in altered protein amounts or when they code for aberrant forms of proteins, may be responsible for some of the observed differences between individuals in their physiological, biochemical, and behavioral responses to those drugs. The acquisition and persistence of, relapse to, and treatment of the addictions may also be influenced by genetic variations.

Although some diseases, such as sickle cell anemia and cystic fibrosis, are single gene disorders, vulnerability to addiction undoubtedly has a more complex genetic basis. Complex diseases may be polygenic (being caused by many genes), but are generally considered to be oligogenic (when only a few genes play a significant role). Classical pharmacogenomics has concentrated on the genetics of an individual and how it relates to their response to therapeutic agents. This has focused on genetic variation related to the absorption, toxicity, and biotransformation of therapeutic agents. However, it has become apparent that physiogenetics, the genetic variability in physiological processes (e.g., endocrine regulation, intercellular signal transduction pathways, and neurochemistry), are of importance. Hence, pharmacogenetics will expand its scope to include physiogenetics.

Many genes have been significantly associated or have displayed evidence of linkage with opiate or cocaine addiction. However, only a small subset of these genes has a polymorphism for which an alteration in function has been verified. Polymorphisms in genes may modify transcriptional regulation or rate, mRNA splicing or stability, protein translation, function (such as enzymatic activity or binding), or stability. There are many factors that may confound results obtained in association or linkage studies, such as population admixture or environmental variables. These factors may obscure the influence of various genetic polymorphisms in the specific cohorts studied, not allowing the studies to reach significance.

In this review, we will discuss several genes for which convincing evidence has been published to indicate that they may be involved in the predisposition to opiate or cocaine addiction. These genes have been chosen due to either a functional alteration in a variant allele affecting expression of this gene, because genetic linkage and/or association have been replicated in a number of different studies and populations, or due to their known role in the manifestation of drug effects. Hence, the genes chosen here for review are hypothesized to be involved in the vulnerability to develop opioid or cocaine addiction based on laboratory studies and, moreover, have been shown to be involved in vulnerability in one or more studies (see Table 1).

A. Epidemiology

Three main factors contribute to the development of addiction. These are: 1) environmental factors, 2) drug-induced physiological effects (such as those effects on neurochemistry, neural networks, mRNA, peptide and protein levels), and 3) genetic factors. Genetic factors may be quite complex in nature. Genetic variants of one gene may interact with other genes, or the effects of one
gene may mask the effect of another gene (epistasis). Genes have been shown to interact with environmental factors. For example, Caspi and colleagues have found that in males with a variant of the monoamine oxidase A gene encoding a monoamine oxidase A enzyme with low activity (a possible risk factor for violence) and also who had experienced high levels of maltreatment as children had the highest risk of developing antisocial behavior (Caspi et al., 2002). Drug addictions are complex disorders that are likely to involve multiple genes having multiple polymorphisms that work in various combinations with each other in different people and interact with the environment. In addition, many of these alleles may contribute to either protection from, or vulnerability to, the development of a drug addiction and will have frequencies which vary by ethnic/cultural group. The genetic, developmental, and environmental context in which particular variants exist may affect their influence on the ultimate phenotype.

Early studies to determine whether addiction is a heritable disease were family studies on alcoholism (e.g., Kaj, 1960; Partanen et al., 1966; Cloninger et al., 1981). More recently, other addictions have been studied and both similarities and differences between the addictions have been observed. Some of the physiology, neurobiology, and treatments have been found to overlap in various aspects between the addictions, but often they are quite distinct. In addition, genetic variants may be both nonspecific (shared) and specific for various drugs of abuse. However, rigorous studies by leading geneticists into the specificity of genetic factors have found divergent results. For example, the genetic influences determining drug abuse vulnerability were studied by Tsuang and colleagues (Tsuang et al., 1998). Using a study population of 3372 predominately Caucasian (90% non-Hispanic white) male twin pairs, it was found that stimulant abuse/addiction (e.g., cocaine and amphetamines) had a total genetic variance of 0.3, whereas heroin use/addiction had a total genetic variance of 0.5. In this study, stimulants had a low specific genetic variance of 0.09, whereas heroin had a high specific genetic variance of 0.4. A similar study, but with very different findings, was performed by Kendler and colleagues using 1196 U.S. Caucasian male twin pairs (Kendler et al., 2003).

Common additive genetic factors for use of cocaine were estimated to have a variance of 0.5, whereas for opiates the variance was estimated at 0.4. However, in contrast with the study of Tsuang and colleagues, the substance-specific additive genetic variance was only 0.07 for cocaine and 0.00 for opiates.

Family studies have also documented familiar transmission of cocaine abuse. Siblings of cocaine-dependent probands had a relative risk of 1.7 to develop cocaine dependence themselves (Bierut et al., 1998). A comparison of other addictions occurring in the probands suggested that the addictions had independent causative factors. Another family study found that the adjusted odds ratio for having the same drug disorder in adult first-degree relatives was over 7 for cocaine and over 10 for opioids, again indicating an involvement of genetic factors (Merikangas et al., 1998).

B. Molecular Genetic Studies

1. Family and Linkage Studies. There are two main types of studies, linkage and association studies, conducted to establish whether genes and their variants may be involved in vulnerability to drug addiction. Linkage studies use families to provide evidence of how close a genetic marker is to an allele causing the phenotype in question, whereas association studies may be performed with unrelated individuals or with parent-offspring trios.

Linkage studies have been used to study subjects with addictive diseases and comorbid conditions. One early and continuing study is the Collaborative Study on the Genetics of Alcoholism (COGA), a multicenter effort to identify genes involved in alcoholism (description available at "www.niaaa.nih.gov/extramural/projcoga.htm") (Edenberg, 2002; also, see Begleiter et al., 1999). This group, as well as studies by others, have identified many chromosomal regions (including regions on chromosomes 1, 2, 3, 4, 7, and 11) using linkage scans that appear to be involved in the vulnerability to develop alcoholism as well as other addictions (Long et al., 1998; Reich et al., 1998; Foroud et al., 2000; Bergen et al., 2003; Ma et al., 2003; Stallings et al., 2003; Wyszynski et
al., 2003). These studies have identified regions that can be more finely mapped, and the genes within these regions may be studied further.

2. Case Control-Association Studies. Another method to identify variants involved in addictions is to select genes that are likely to be involved in the physiological effect of the specific drug under consideration in a neurotransmitter system related to drug taking behaviors or genes for which there is previous evidence to be of interest. Genetic variants are identified in these candidate genes. Cases and control groups are genotyped for the variant(s), and statistical approaches are then employed to measure the probability that a given variant allele is associated with the drug addiction.

In association studies, the cultural identity and the ethnicity of the subjects must be carefully evaluated because some genes’ allelic frequencies vary widely among ethnic/cultural groups. Several studies have found that although approximately 90% of the total genetic variation is between individuals, approximately 10% occurs between ethnic/cultural groups (reviewed in Brown and Armelagos, 2001). Hence, it appears that this 10% difference may be enough to introduce population stratification into association analyses when ethnicity is not matched between subjects and controls. Failure to do so may cause both false-positive and false-negative errors. Such population admixture, or stratification, repeatedly has been shown to confound results of association studies (reviewed in Thomas and Witte, 2002).

The techniques for conducting association studies have been recently expanded to include thousands of variants using gene microarray technology. To locate and identify genes and chromosomal regions that are associated with specific addictions, genome-wide scans can be performed on affected and control subjects. To map genes involved in vulnerability to drug abuse, Uhl and colleagues have used microarray technology (using an Affymetrix microarray that can genotype 1494 SNPs in a single hybridization) (Uhl et al., 2001).

Multiple pools, each containing DNA from 20 individuals who were either polysubstance abusers or controls and who were of the same ethnic/cultural group, were genotyped. Using this association genome scanning technique, they identified 42 chromosomal regions that potentially are involved in vulnerability to drug abuse in both European Americans and African Americans. Since these studies were conducted using subjects with alcohol, nicotine, or polysubstance addictions, the chromosomal regions identified may contain loci for vulnerability to addiction to multiple substances. When the variants associated with polysubstance abuse in the microarray study were compared with those regions identified in linkage studies of alcohol (Long et al., 1998; Reich et al., 1998; Foroud et al., 2000) and nicotine addiction (Straub et al., 1999), 15 candidate regions had positive results in at least two of the studies (Uhl et al., 2002b). Again, since these studies were based on polysubstance abuse, alcohol, or nicotine addiction, the regions identified as candidates are most likely associated with vulnerability to drug abuse in general.

3. Haplotype Analysis. Polymorphic variants are known to associate in clusters. Analyses of variants in pedigrees have shown that some alleles that are in close proximity with each other are inherited as a block, whereas others have lower linkage disequilibrium. Linkage disequilibrium patterns of variants have shown that there are characteristic patterns of linkage disequilibrium across the human genome. A map of these patterns is a haplotype map and is a description of variants in a region and the linkage disequilibrium pattern involved. The haplotype map is intended to describe the common variation patterns and to provide a minimal set of variants that capture the full set of diversity in the population.

A haplotype is a defined region of one chromosome from each pair of chromosomes. An individual has two sets of haplotypes, one derived from each parent. Hence, haplotype blocks in a population represent chromosomal regions that were inherited with little past recombination. Haplotypes may be determined directly through the use of various techniques or may be inferred using one of several algorithms. These algorithms predict haplotypes that are most likely to occur. However, haplotypes of equal likelihood are not predicted by these methods, although they may be the real haplotypes.

Haplotypes vary among populations. It has been demonstrated that in European and Asian populations the mean haplotype block is about 22,000 nucleotides with about four common haplotypes per block (Gabriel et al., 2002). In African American and Yoruban (Nigerian) populations, the mean haplotype block is only 11,000 nucleotides with five common haplotypes per block. This is similar to the finding of Reich and colleagues who found that, in populations of European descent, linkage disequilibrium extends to approximately 60,000 nucleotides from common alleles, although only extending less than 5000 nucleotides in a Nigerian population (Reich et al., 2001).

When a new variant arises in a population, it occurs on a specific haplotype. In subsequent generations, the variant and its ancestral haplotype are altered only by recombination or the acquisition of new variants. Hence, it should be possible to identify a rare variant associated with a disease by identifying the ancestral region on which it was first introduced.

Two examples relevant to this review which will be detailed below are the μ opioid receptor (OPRM1) and dopamine β-hydroxylase (DBH) genes. A haplotype analysis of OPRM1 was conducted with European American and African American subjects (Luo et al., 2003). Eight variants were genotyped and analyzed using an expectation-maximization (E-M) algorithm (Long et al., 1995). Six haplotypes were predicted in the European Americans and seven in the African Americans. In the Euro-
pean Americans, a significant difference in haplotype frequency was found between the groups who were both alcohol- and opioid-dependent combined versus controls.

In the DβH gene, Cubells and colleagues genotyped two variants, one 3000 nucleotides upstream of the transcription start site (DBH*5'-ins/del) and the other at nucleotide 444 (DBH*444g/a) (Cubells et al., 2000). These variants, separated by approximately 8400 nucleotides, were in linkage disequilibrium. One of the haplotypes, “Del-a”, was associated with low plasma D

These variants, separated by approximately 8400 nucleotides, were in linkage disequilibrium. One of the haplotypes, “Del-a”, was associated with low plasma DβH and with cocaine-induced paranoia in European Americans.

C. Selected Identified Genes

1. Opioid-Related Genes. For millennia, compounds derived from the opium poppy have been used for their medicinal properties as analgesics, antitussives, soporifics, and antidiarrheals. Also, opium and derivatives such as morphine and heroin have long been recognized as drugs of addiction. Endogenous receptors for opiate drugs were first postulated to exist in 1954 (Beckett and Casey, 1954). During the ensuing two decades, efforts to identify these receptors were performed using stereo-specific ligand-binding assays (Ingoglia and Dole, 1970; Goldstein et al., 1971), and in 1973, opioid receptors were discovered independently by three groups (Pert and Snyder, 1973; Simon et al., 1973; Terenius, 1973). The availability of increasingly selective opioid ligands subsequently allowed the identification of three receptor types, which were named the μ, κ, and δ opioid receptors (abbreviated in this review as MOR, KOR, and DOR, respectively). The first endogenous ligands for opioid receptors were identified in 1975 by Hughes and colleagues, who isolated Leu- and Met-enkephalins, which are five amino acid peptides with “opiate-like” or “opioid” activity (Hughes et al., 1975). Subsequently, two other endogenous opioid peptides were discovered, β-endorphin and dynorphin A (Bradbury et al., 1976; Cox et al., 1976; Li and Chung, 1976; Goldstein et al., 1979).

The endogenous opioid peptides are derived through proteolytic processing of three propeptide precursors. Met- and Leu-enkephalin, as well as Met-enkephalin-Arg-Phe and Met-enkephalin-Arg-Gly-Leu are derived from proenkephalin. β-Endorphin is derived from proopiomelanocortin (which also yields adrenocorticotropic hormone and melanocyte stimulating hormone in equimolar amounts), and processing of prodynorphin produces dynorphins A and B and α-neoendorphin. Each of these classic endogenous opioid peptides contains the N-terminal sequence Tyr-Gly-Gly-Phe, which confers their opiate-like properties.

The cDNA and gene sequences of the endogenous opioid peptide precursors were determined a few years after their discovery (enkephalin: Comb et al., 1982; Noda et al., 1982a,b; dynorphin: Kikidani et al., 1982; Horikawa et al., 1983; pro-opiomelanocortin: Nakanishi et al., 1979, 1981; Takahashi et al., 1981, 1983). Opioid receptors, on the other hand, were first cloned and sequenced almost 20 years following their discovery. The groups of Evans and Kieffer, working independently, isolated, defined, and sequenced cDNA clones of the mouse δ opioid receptor in 1992 (Evans et al., 1992; Kieffer et al., 1992). Following publication of the sequence of the DOR, many groups used homology screening to identify and sequence clones of the MOR and KOR from several species (μ: Chen et al., 1993; Fukuda et al., 1993; Thompson et al., 1993; Wang et al., 1993; κ: Li et al., 1993; Meng et al., 1993; Minami et al., 1993; Yasuda et al., 1993; Mansson et al., 1994; Simonin et al., 1995, Zhu et al., 1995; δ: Knapp et al., 1994; Simonin et al., 1994).

Binding assays with selective ligands allowed classification of the opioid receptors into three general classes: the MOR, which has as endogenous ligands the enkephalins and β-endorphin, the DOR, which selectively binds enkephalins, and the KOR, for which dynorphins are the endogenous ligands. Binding assays using cells expressing cloned receptors indicate that there exists considerable cross-selectivity for some of the peptide ligands.

The endogenous opioid system is centrally important in the responses to addictive opiate drugs such as morphine, codeine, and heroin, as well as to synthetic opioid narcotics such as fentanyl. The receptors mediate both the analgesic and rewarding properties of opioid compounds and opioid effects on the hypothalamic-pituitary-adrenal (HPA) stress-responsive axis, respiratory and pulmonary function, gastrointestinal motility, immune responses, and other functions. Additionally, this system is important in modulating the responses to cocaine and other psychostimulants, as well as to alcohol and other drugs (e.g., see Kreek et al., 2002). Components of the endogenous opioid system and the genes encoding them have therefore been the focus of research into specific addictions since their discovery.

a. μ Opioid Receptor Gene (OPRM1). OPRM1 has been selected as a candidate for human genetic studies of the addictions for many reasons. The MOR is the molecular target of the active biotransformation products of heroin (6-monoacetylmorphine and morphine), as well as most opiate and opioid analgesic medications such as oxycodone, hydromorphone, and fentanyl, each of which has significant potential for addiction. Abuse of and addiction to these MOR-directed agents is increasingly recognized to constitute a major addiction problem. From our early work that led to the development of methadone maintenance treatment for heroin addiction in the 1960s, we know that μ-selective agonists with long-acting pharmacokinetics such as methadone and levo-α-acetylmethadol (LAAM) or partial agonists (buprenorphine) are the most effective treatments for this disorder (e.g., Dole et al., 1966; Kreek et al., 2002). Clinical studies also point to a relative “endorphin deficiency” in active and former heroin addicts and also in
active or recently abstinent cocaine addicts, although whether this is drug-induced or pre-exists and contributes to the development of addiction is still an unanswered question (e.g., Kreek et al., 1984; Schluger et al., 2001).

Studies of quantitative trait loci in mice identified a chromosomal region containing the μ opioid receptor gene as contributing to a substantial amount of the variance in analgesic and reward responses to morphine (Belknap and Crabbe, 1992; Berrettini et al., 1994; Kozak et al., 1994; Belknap et al., 1995; Crabbe et al., 1999). Also, studies of mice with targeted deletion of the μ opioid receptor gene definitively established this receptor as essential for morphine analgesia, physical dependence, and reward as measured by antinociception, withdrawal, conditioned place preference, and self-administration studies (Matthes et al., 1996; Sora et al., 1997; Kitanaka et al., 1998; Loh et al., 1998; Becker et al., 2000). Chronic morphine administration or heroin self-administration alters naloxone efficacy measured using 5'-3-(35S)thiotriphosphate (35S)GTP-S binding in several brain regions by increasing MOR binding and decreasing MOR-activated G proteins (Sim et al., 1996; Sim-Selley et al., 2000; Kruzich et al., 2003).

Although the initial molecular target of cocaine is monoamine transporters, expression and function of the MOR is also affected by cocaine, particularly in a chronic experimental administration paradigm and also in long-term human cocaine abusers. For example, in rats administered cocaine for 14 days in a “binge” paradigm, MOR binding density increased in several regions containing terminals of the mesocorticolimbic dopaminergic system, including areas of the cingulate cortex, the nucleus accumbens, caudate-putamen, and basolateral amygdala (Unterwald et al., 1992, 1994). A direct molecular effect of acute or 3-day cocaine administration on MOR mRNA levels has also been observed with increases in dopaminergically innervated brain regions reported (Azaryan et al., 1996; Yuferov et al., 1999). A positron emission tomography (PET) study in cocaine-dependent men also showed increases in MOR binding that were associated with cocaine craving (Zubieta et al., 1996). Additionally, MOR knockout mice show reduced reward responses to both cocaine and alcohol (Roberts et al., 2000; Hall et al., 2001; Becker et al., 2002).

Many variants, particularly SNPs, in the coding, untranslated, flanking, and intronic regions of this gene have been identified and tested for association with opiate, cocaine, and other addictions. A few nonsynonymous variants in the coding region have been studied using in vitro assays to assess possible functional alterations in the encoded proteins.

The most common coding region SNP, the A118G variant, which alters amino acid sequence, was one of the first discovered in the OPRM1 gene (Bergen et al., 1997; Bond et al., 1998) and has been evaluated in a number of genetic studies of opiate, alcohol, and mixed drug addiction. This variant has also been shown to be of physiogenetic (genetically based difference in physiology) and pharmacogenetic (genetically based difference in response to a pharmacotherapeutic agent) importance, discussed below. The frequency of this polymorphism varies widely across populations, occurring at less than 2% in some populations up to almost 50% in others (Table 2). This SNP is in the first exon of the OPRM1 gene, and the 118G allele encodes a variant receptor with an aspartic acid at amino acid position 40 instead of asparagine, which is at this position in the prototype receptor. This substitution leads to a charge difference and also to the loss of a putative N-linked glycosylation site in the N-terminal domain of the receptor (Bergen et al., 1997; Bond et al., 1998). Glycosylation of G protein-coupled receptors has been reported to be important in mediating appropriate protein conformation that allows receptor trafficking to the cell membrane (George et al., 1986; Hughes et al., 1997; Petäjä-Repon et al., 2000).

In an extensive in vitro study of function of the variant receptors encoded by the 118A and 118G alleles, we used

---

**TABLE 2**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Caucasian</td>
<td>0.105 (100)</td>
<td>0.115 (52)</td>
<td>0.141 (543)</td>
<td></td>
<td></td>
<td>0.107 (187)</td>
<td>0.109 (559)</td>
</tr>
<tr>
<td>European American</td>
<td>0.122 (324)</td>
<td></td>
<td></td>
<td>0.442 (137)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finnish</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swedish</td>
<td>0.485 (34)</td>
<td>0.362 (297)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japanese</td>
<td>0.142 (67)</td>
<td>0.117 (47)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Han Chinese</td>
<td>0.146 (165)</td>
<td>0.351 (208)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chinese</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malay</td>
<td>0.1016 (31)</td>
<td>0.028 (144)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>0.163 (367)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Southwest Native American</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>0.170 (49)</td>
<td>0.080 (43)</td>
<td>0.210 (93)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Note:** The values represent the allelic frequencies of the variant (118G) allele of the A118G single nucleotide polymorphism of the OPRM1 gene in diverse populations.
stably transfected cell lines expressing either the variant or prototype receptors and performed binding assays using several ligands, including the five amino acid residue endogenous peptide ligands Met- and Leu-enkephalin, the four amino acid residue peptides endomorphin-1 and -2, the synthetic µ-selective peptide D-Ala²,N-Me-Phe³,Gly-ol⁴-enkephalin, the κ-selective endogenous peptide dynorphin A(1–17), the µ-preferring opioid agonists morphine, methadone, fentanyl, and the opioid antagonist naloxone. Each of these compounds had similar binding affinities to the prototype and 118G variant receptors (Bond et al., 1998).

We also tested the µ- and δ-selective 31-residue endogenous peptide β-endorphin, which is the longest of the endogenous opioid peptides, has the longest half-life, and is found both centrally and peripherally. In our in vitro studies, β-endorphin bound the 118G variant receptors with approximately three times greater affinity than those containing the prototype sequence (Bond et al., 1998).

We also studied the 118A and 118G variant receptors with respect to an important cellular activity of the MOR, that of agonist-mediated regulation of G protein-activated inwardly rectifying K⁺ channels. The prototype or 118G receptors were coexpressed in Xenopus oocytes with G protein-activated inwardly rectifying K⁺ channels; several peptide agonists, including β-endorphin and endomorphin-1 and -2, were tested for their ability to activate the K⁺ channels. The short peptide agonists tested in this assay all showed similar EC₅₀ values for the prototype and variant receptor; however, β-endorphin caused an approximately 3-fold greater potency in activation of K⁺ current in the 118G variant receptor compared with the prototype (Bond et al., 1998).

The differences in binding of β-endorphin and activation of the 118G variant receptors following β-endorphin binding in these in vitro cellular studies led us to predict that persons carrying the gene expressing the variant receptor might show altered function of physiological systems under the control of the MOR, including, for example, pain perception, reproductive function, and responses to stress mediated by the HPA stress-responsive axis, which is under tonic inhibitory control of this receptor (Bond et al., 1998; Kreek 2000; LaForge et al., 2000b). Two studies have identified such a difference in the HPA stress-responsive axis of persons with the 118A/118G or 118G/118G genotype (Wand et al., 2002; Hernandez-Avila et al., 2003). In these studies, healthy control individuals were administered naloxone; subjects who carried one or more 118G alleles showed a greater activation of the axis, as measured by plasma cortisol, demonstrating a physiogenetic role for the A118G variant. Additional studies also suggest that this polymorphism may result in altered pharmacogenetic responses. Differences in physiological and analgesic responses to morphine, its active metabolite morphine-6-glucuronide (M6G), and to alfentanil have been reported in individuals carrying a 118G allele (Lötsch et al., 2002; Skarke et al., 2003a). Also, 118A/118G or 118G/118G genotypes have been reported to be associated with an improved response to treatment of alcoholism with naltrexone (Oslin et al., 2003) as well as to treatment of smoking with transdermal nicotine replacement therapy (Lerman et al., 2004).

The A118G variant has been studied in a number of genetic studies, primarily case-control studies of opiate and other addictions. In some studies, evidence for an association of specific alleles in specific populations has been found; other studies have not obtained such evidence. In the first report of an association of this variant with opiate addiction, we observed a higher proportion of the 118G allele in Hispanic control subjects, but not in American Caucasian or African American subjects (Bond et al., 1998). Tan and colleagues found a higher proportion of the 118A allele in opioid-dependent cases of Indian ancestry who were recruited and studied in Singapore; this finding, however, was not replicated in other ethnic groups in that study, including Chinese and Malay subjects (Tan et al., 2003). In both of these studies, the numbers of individuals in each of the groups with a positive association was small (58 cases and 9 controls in the study of Bond and colleagues, 20 cases and 117 controls in the study of Tan and colleagues); also, the likelihood of population admixture in these groups would be expected to be high, which may have contributed to the findings of a positive association with this allele.

Conversely, in two other studies conducted in selected populations, the 118G allele was found to be strongly associated with opiate addiction. These studies had a more robust sample size and, to reduce the possibility of admixture confounding results, were performed with subjects who had parents of the same ethnic/cultural group as the probands. Szeto and colleagues studied 200 cases and 97 controls. Subjects were male Han Chinese individuals with all first-degree relatives from that ethnic group. An association of both the 118G allele and genotypes containing that allele with opiate-dependent subjects was found (Szeto et al., 2001).

In a recent study of heroin addiction in subjects from a geographic region known to have minimal admixture (central Sweden) we studied primarily Swedish individuals (both male and female) from the Stockholm area (139 cases and 170 controls). Like the study of Szeto and colleagues, we observed an association of 118G alleles and genotypes containing at least one 118G allele with opiate addiction (Bart et al., 2004a). Moreover, in that study, we found a substantial attributable risk for heroin addiction contributed by the 118G allele. In this study, the findings were significant if all subjects were included (attributable risk 18%), as well as if analyses were limited to Swedish subjects with both parents Swedish (attributable risk 21%) (Bart et al., 2004a).
Other genetic studies in which the A118G SNP has been evaluated have not found evidence that either allele of the A118G variant is associated with the development of opiate addiction. These include two studies of Han Chinese populations in Sichuan and Nanjing Provinces, respectively, one of German Caucasians and one in a sample of American Caucasians and African Americans (Li et al., 2000; Franke et al., 2001; Shi et al., 2002; Crowley et al., 2003). Li and colleagues studied 282 heroin-abusing subjects (DSM-IV criteria, determined by clinical interview) and 258 control subjects without neurological or psychiatric disorders (determined by questionnaire) recruited from college staff, medical students, and acute medical inpatients from a general hospital. All subjects were Han Chinese recruited in the Sichuan Province. No differences in genotype or allele frequencies between cases and controls were observed (Li et al., 2000). Franke and colleagues used case control and allele transmission analyses to test for an association of the A118G SNP with opiate addiction in German Caucasians from the Bonn area. In the case control analysis, 287 individuals meeting DSM-III-R criteria for opiate dependence and 365 control subjects (with 133 screened using a semistructured instrument and 232 blood donors who were briefly screened with respect to drug abuse history) were genotyped for the A118G variant. No differences in genotype or allele distributions were observed between cases and controls (Franke et al., 2001). Shi and colleagues studied 148 former heroin addicts in methadone maintenance test with 111 opiate-dependent probands, no preferential transmission of alleles of the A118G SNP were found within control matched for ethnicity (European American and African American) recruited from the Philadelphia area. No differences between cases and controls in genotype or allele frequencies for the A118G SNP were found within either ethnic group (Crowley et al., 2003).

The second most common coding region variant of the \( \mu \) opioid receptor gene is the C17T SNP, which encodes a variant receptor with a valine at amino acid position 6 instead of alanine in the N-terminal domain of the receptor (Bergen et al., 1997; Berrettini et al., 1997; Bond et al., 1998). Allele frequencies of this substitution also vary widely across population groups (Table 3). The potential functional significance of this alteration in protein structure was studied with no differences between prototype and variant receptors in agonist binding to several peptide and nonpeptidic ligands, in agonist-induced \( 5'-O-(3-[35S]\text{thio})\text{triphosphate (}\text{[35S]}\text{GTP}\gamma\text{S}) \)-binding assays (a measure of receptor activation), or in agonist-mediated receptor down-regulation (Befort et al., 2001). It should be noted, however, that in this study no differences in \( \beta \)-endorphin binding between the 118A and 118G receptors were found and that an undefined biological reason (such as systematically decreased presentation of functional receptors on the plasma membrane) or, alternatively, technical matters may underlie the difference in findings with our earlier study in which binding differences were observed (Bond et al., 1998).

Several studies have also evaluated this variant with respect to specific addictions in human genetic studies. Berrettini and colleagues reported that the 17T allele was associated with opiate- and/or cocaine-dependent subjects at a borderline level of significance (\( p = 0.05, \)

### Table 3

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Asian</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Japanese</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Han Chinese</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chinese</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.005 (209)</td>
<td></td>
</tr>
<tr>
<td>Thai</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None observed (56)</td>
<td></td>
</tr>
<tr>
<td>Malay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.005 (156)</td>
<td></td>
</tr>
<tr>
<td>Indian</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None observed (137)</td>
<td></td>
</tr>
<tr>
<td>Southwest Native American</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>European American</td>
<td>0.019 (52)</td>
<td>0.008 (470)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Finnish</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swedish</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.037 (66)</td>
<td>0.011 (46)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>0.210 (31)</td>
<td>0.140 (143)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (populations in Israel)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethiopian</td>
<td>0.080 (49)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bedouin</td>
<td>0.050 (43)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ashkenazi</td>
<td>0.016 (93)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ethnic groups combined), a finding similar to our study of opioid-dependent individuals in which individuals were stratified by ethnic/cultural group (Berrettini et al., 1997; Bond et al., 1998). Two studies in other populations did not find an association of this variant with alcohol or mixed (opiate and/or cocaine) dependence (Gelernter et al., 1999). Because the 17T allele is at low frequency or absent in a number of the populations in which this variant has been characterized, its usefulness as a genetic marker may be limited to those populations in which it has a higher prevalence (see Table 3, and Bond et al., 1998; Gelernter et al., 1999; Tan et al., 2003; Bart et al., 2004a,b).

Several other variants, primarily SNPs, of the μ opioid receptor gene have been evaluated in the context of opiate, cocaine, and other addictions. For example, an allelic association was reported for the IVS2 C1031G variant in male Han Chinese with both parents also from that ethnic group (Szeto et al., 2001); however, this finding was not observed in a separate study in several populations including Han Chinese, Indian, Thai, and Malay individuals recruited in Singapore (Tan et al., 2003).

Three groups have also reported haplotype approaches to test for associations of this gene with addiction to opiates with or without addiction to other substances. One study used a clustering approach of 43 variants in coding, flanking, and intronic regions in a study group of European Americans and African Americans with opiate and/or cocaine dependencies compared with ethnically matched controls; they reported that specific haplotypes were associated with addiction to these substances (Hoehe et al., 2000). This type of analysis, however, raises issues concerning corrections for multiple testing, an issue that has come under increasing scrutiny in the field of statistical genetics (Levenstien et al., 2003). A second study of six biallelic variants (C-2044A, T-1793A, -1699 insT, T-1469C, A-1320G, and C-111T) in the 5′-flanking region along with the A118G and C17T SNPs, reported specific differences in haplotype frequencies comparing controls to alcohol- and opioid-dependent patients combined or to alcohol- and/or cocaine-dependent patients combined or to alcohol-, opioid-, or cocaine-dependent patients combined (DSM-III-R criteria), although this finding was limited to European American subjects and was not found in African Americans (Luo et al., 2003). An additional study conducted in European American and African American subjects evaluated three 5′-flanking region variants (T-1793A, -1699 insT, and A-1320G) along with the two common exon 1 SNPs and did not find evidence for an association of haplotypes with severe opiate dependence (cases had a family history of substance dependence and the age of onset of opiate dependence was 20 or below) (Crowley et al., 2003). In each of the haplotype studies, significant differences in haplotype frequencies were found between the two ethnic/cultural groups. Also, a high degree of linkage disequilibrium was reported across the 5′-flank-
Recently, Yuferov and colleagues defined an additional 5' exon in the human \( \kappa \) opioid receptor gene and identified several transcription initiation sites, as well as determining the poly(A) addition site of the mRNA (Yuferov et al., 2004). This has allowed a renumbering of the exons of the gene, and the previously numbered exons 1, 2, and 3 will be referred to as 2, 3, and 4 in this review.

Seven SNPs in the human \( \kappa \) opioid receptor gene have been reported (Höltt, 2000; LaForge et al., 2000a; Mayer and Höltt, 2001). These include the substitutions G36T in exon 2, C459T in exon 3, and A843G, C846T, C852T, C948T, and C1008T in exon 4. The first to be reported were identified in a population of German Caucasians; these were G36T (14%), C459T (2%), C843C (8%), and C846T (2%) (Höltt, 2000) (with allele frequencies in parentheses reported in Mayer and Höltt, 2001). These variants were also detected in our further studies conducted in New York with a study sample of primarily Caucasian, African American, and Hispanic subjects with the identification of additional SNPs that have overall allele frequencies ranging from <1% to 3% (Yuferov et al., 2004). Additionally, preliminary evidence from that study suggests that the G36T SNP may be associated with opiate addiction (Yuferov et al., 2004).

c. \( \delta \) Opioid Receptor Gene (OPRD1). The DOR functions in nociceptive responses, but has also been shown to be involved in modulating the effects of MOR-directed compounds. For example, mice with targeted deletion of the OPRD1 gene do not develop tolerance to the analgesic effects of morphine, although still becoming physically dependent on the drug (Zhu et al., 1999; Nitsche et al., 2002). The DOR also may play a role in responses to cocaine. Chronic binge cocaine administration attenuated the ability of the selective \( \delta \) agonist [\( \delta \)-penicillamine, \( \delta \)-penicillamine] enkephalin to inhibit adenylyl cyclase in the caudate-putamen and nucleus accumbens (Unterwald et al., 1993).

Three studies have evaluated variants of the OPRD1 gene for possible association with opiate addiction. Cloning of the OPRD1 identified three exons containing the complete coding region; however, given that the rat and mouse genes have four exons, the possibility of yet undiscovered exons remain (Simonin et al., 1994). Two coding region SNPs in the OPRD1 gene have been defined and studied. These are both in the first exon: a T80G substitution, which results in the replacement of the amino acid phenylalanine with cysteine at position 27, and the synonymous substitution T921C (Mayer et al., 1997; Gelernter and Kranzler, 2000).

Mayer and colleagues studied 103 heroin addicts from the Rhine-Ruhr, Berlin, and Southern Bavaria areas of Germany and 115 unaffected individuals from the Rhine-Ruhr and Southern Bavaria regions, with the T921C variant ascertained in cases and controls (Mayer et al., 1997). This SNP is very common in this population, with 39% frequency of the 921C allele in control subjects. This study identified an association of the 921C allele with opiate addiction. No differences in genotype or allele frequencies were observed between samples collected from different regions within Germany within the case or control groups, respectively.

In a second study of 233 German heroin addicts meeting DSM-III-R criteria for heroin dependence and 173 ethnically and geographically matched controls (all subjects were from the Bonn area), no differences were found in genotype or allele frequencies for the T921C SNP between cases and controls (Franke et al., 1999). Also, an allele transmission test was performed on 90 additional heroin addicts and their parents. No difference in allele transmission to affected offspring was detected (Franke et al., 1999). A third study analyzed the OPRD1 T921C SNP in 405 patients hospitalized for heroin detoxification (all meeting DSM-IV criteria for opiate abuse or dependence) from two cities in Southwestern China and population-based controls from the same geographic region (Xu et al., 2002). In this study, no differences were observed in genotype or allele frequencies between cases and controls. Genotyping of two unrelated (genomic control) variants (ADH2 47 His>Arg and ADH2 487 Glu>Lys) suggested that cases and controls were appropriately matched in this sample. These studies bring into question the findings of Mayer and colleagues, and additional studies in diverse populations will be necessary to determine the importance of variants of the OPRD1 gene in the development of opiate addiction.

d. Preproenkephalin Gene (PENK). Enkephalin peptides, which are derived from the processing of proenkephalin, function in the modulation of pain perception and are also suggested to play a role in reward and the addictions. For example, “knockout” mice lacking the preproenkephalin gene, develop physical dependence following morphine administration but do not develop tolerance to the antinociceptive effects of the drug (Nitsche et al., 2002). Additionally, mice lacking the enkephalin gene show reduced responding to food reinforcers, which suggests a general reduction in hedonic response (Hayward et al., 2002).

One study of 31 opioid-dependent non-Hispanic Caucasians and several matched control/contrast groups found an association of genotypes and alleles of a (CA)\(_n\) repeat polymorphism in the 3'-flanking sequence and opiate dependence, as measured by DSM-III-R criteria (Comings et al., 1999). Preliminary findings of studies conducted by our group also suggest a difference in genotype frequencies between opioid-dependent cases and controls in Caucasian subjects, but not in other ethnic/cultural groups studied (K. S. Laforge, unpublished findings).

e. Preprodynorphin Gene (PDYN). As discussed above, naturally occurring peptides derived from prodynorphin (including dynorphin A, dynorphin B, and
α-neoendorphin) are the primary endogenous ligands of the κ opioid receptor. Microdialysis studies in rats demonstrated that dynorphin A(1–17) lowers basal dopamine tone in the nucleus accumbens, and studies in mice demonstrate that this peptide attenuates the increases in dopamine release in the nucleus accumbens caused by cocaine administration (Claye et al., 1997; Zhang et al., 2004). It is therefore hypothesized that dynorphins acting through the κ opioid receptor may counter-modulate the responses of the dopaminergic system to psychostimulants and, possibly, other drugs of abuse that also directly or indirectly increase synaptic dopamine release in brain reward circuitry. The well-documented increases in striatal dynorphin peptide release and increases in mRNA levels caused by psychostimulant administration provide additional evidence that dynorphin is relevant for addictions (e.g., Sivam, 1989; Hurd and Herkenham, 1992; Hurd et al., 1992; Daunais et al., 1993; Spangler et al., 1993a,b).

Variants of the preprodynorphin gene have been studied in addiction to opiates, cocaine, and alcohol, as well as in in vitro functional studies. The most interesting variant is a 68-base repeat polymorphism located in the promoter region. This repeat was identified in the initial sequencing report of the gene (Horikawa et al., 1983) and is located approximately 1200 nucleotides upstream from the primary transcription initiation site identified by Geijer and colleagues (Geijer et al., 1995), thus placing it in the putative promoter region of the gene. Zimprich and colleagues studied this region in heroin addicts and controls and showed that the repeat is polymorphic, with alleles of one, two, three, and four copies identified (Zimprich et al., 2000). In that study, the alleles had overall frequencies of 2.7%, 32.0%, 63.5%, and 1.8%, for the one, two, three, and four repeat alleles, respectively, in control subjects of German Caucasian origin. Interestingly, the repeat contains a near-canonical activator protein 1 (AP-1) binding site that specifically binds the AP-1 protein complex. Using reporter gene constructs containing one to four copies of the repeat, Zimprich and colleagues also found that phorbol ester-induced transcription was greater in cells transfected with plasmids containing three or four copies of the repeat compared with one or two copies, and therefore this 68-base repeat polymorphism represents a potentially functional gene variant (Zimprich et al., 2000).

In their study of this variant and opiate addiction, Zimprich and colleagues found no differences in allele frequencies between heroin-addicted and control subjects (Zimprich et al., 2000). However, given the interactions between cocaine, dopamine, and dynorphin described above, we suggested this variant as an interesting candidate for cocaine addiction (LaForge et al., 2000b; Chen et al., 2002). In our study of cocaine abusing and dependent subjects and controls recruited in New York, we found that alleles containing three or four copies of the repeat were more common in control subjects compared with cases. These findings suggest that longer alleles (i.e., those with three or four copies of the repeat), which may result in greater transcriptional activation of the dynorphin gene and, therefore, greater levels of dynorphin peptides, may be protective against cocaine addiction. Given these provocative findings and the concordance of evidence from human genetic, animal, and in vitro molecular biological studies, further genetic studies into the role of allelic variants of the dynorphin gene in cocaine and other addictions are warranted.

2. Monoaminergic-Related Genes. The monoaminergic neurotransmitter systems include the catecholaminergic and the serotonergic systems. Dopamine, a catecholamine, functions as a neurotransmitter in the central nervous system, whereas norepinephrine, another catecholamine, is also a neurotransmitter in the brain and is the main postganglionic, sympathetic neurotransmitter (Molinoff and Axelrod, 1971). Dopamine is synthesized from the amino acid tyrosine by the subsequent actions of the tyrosine hydroxylase and 3-hydroxytyrosine decarboxylase enzymes. Dopamine can then be biotransformed to norepinephrine by the action of the enzyme DβH. Tryptophan is biotransformed by tryptophan hydroxylase and aromatic amino acid decarboxylase into serotonin. Upon the appropriate signal, e.g., membrane depolarization, the monoaminergic neurotransmitters are released from the presynaptic neurons into the synapse where they bind to both pre- and postsynaptic receptors. The dopamine, serotonin, and norepinephrine transporters then transport dopamine, serotonin, and norepinephrine, respectively, back into the presynaptic neuron for reutilization or degradation. There is a large body of evidence indicating interactions between the dopaminergic, serotonergic, and opioidergic systems in reward and drug dependence and withdrawal (Kreek et al., 2002). The dopaminergic pathways of the mesolimbic and nigrostriatal systems have been shown to be involved in the reward pathway. Disinhibition of dopaminergic neurons in the ventral tegmental area with opioid agonists such as the μ opioid receptor-directed peptides, e.g., β-endorphin, or pharmacological agents activate the reward pathway (Di Chiara and Imperato, 1988a; Herz, 1988).

Cocaine has been demonstrated to activate the expression of many genes in the nucleus accumbens through the downstream changes in adenylyl cyclase which produce an increase in cAMP levels. In response to increased cAMP, CREB (cAMP response element-binding protein) becomes activated via phosphorylation (Nestler, 2001). Phospho-CREB dimerizes with CREB-binding protein to activate transcription through binding to the CRE binding sites of several genes, thereby activating their transcription. Cocaine has been shown to activate a number of target genes in this manner in the nucleus accumbens, including preprodynorphin, preproenkepha-
lin, and several transcription factors (reviewed in McClung and Nestler, 2003).

Serotonin is the neurotransmitter of the serotonergic system. Serotonergic neurons originate in the raphe nuclei of the brain stem and project throughout the brain. Serotonergic function is believed to be involved in impulse control and behavioral suppression (Soubrie, 1986). Medications effective in the treatment of depression, including the prevention of suicidality such as selective serotonin reuptake inhibitors, have the serotonergic system as their sites of action.

Norepinephrine-containing neurons in the central nervous system originate from the locus ceruleus and the lateral tegmental nucleus, both located in the brain stem, and project to the cortex, spinal cord, and cerebellum. The noradrenergic system is involved in the perception of positive motivation. Medications used in the treatment of depression, such as selective serotonin reuptake inhibitors and reboxetine (a nontricyclic antidepressant norepinephrine uptake inhibitor not approved for use in the United States), have been shown in animals to decrease the firing of neurons in the locus ceruleus (Szabo et al., 1999; Szabo and Blier, 2001).

Cocaine’s pharmacological actions are produced, in part, by its high-affinity binding to the dopamine transporter and lower-affinity binding to the serotonin transporter and the norepinephrine transporter by inhibiting reuptake of dopamine, serotonin, and norepinephrine, respectively (Uhl et al., 2002a; Rothman and Baumann, 2003). Mice with targeted disruption of the gene encoding the dopamine transporter or the norepinephrine transporter still retain conditioned place preference (Sora et al., 2001; Hall et al., 2002). However, mice with disruption of both the genes coding for the dopamine and serotonin transporters no longer display conditioned place preference indicating that both of these transporters are involved in cocaine’s action (Sora et al., 2001).

Below we will discuss the relevance of five genes of the monoaminergic system, \( \text{D} \beta \text{H} \), dopamine receptor D2 (\( \text{DRD2} \)), dopamine transporter (\( \text{SLC6A3} \)), serotonin transporter (\( \text{SLC6A4} \)), and norepinephrine transporter (\( \text{SLC6A2} \)). The structure of the three transporter genes and their relevant variants are shown in Fig. 1.

**a. Dopamine \( \beta \)-Hydroxylase Gene (D\( \beta \)H).** The enzyme D\( \beta \)H metabolizes dopamine into norepinephrine (Kaufman and Friedman, 1965; reviewed in Weinshilboum, 1978). Many centrally mediated cognitive, behavioral, and physiological functions are modulated by norepinephrine (Grace et al., 1998; Arnsten, 2000a,b). D\( \beta \)H is found within synaptic vesicles that store catecholamines. Most of the D\( \beta \)H is membrane-bound, whereas some is free within the vesicle (Stewart and Klinman, 1988). D\( \beta \)H is coreleased with catecholamines during synaptic transmitter release from neurons and from the neurosecretory cells of the adrenal medulla into the circulation. D\( \beta \)H is quite stable in plasma, with a 4.2-day half-life in rats (Grzanna and Coyle, 1977). Levels of D\( \beta \)H are highly correlated between the cerebrospinal fluid (CSF) and plasma, but vary widely between unrelated individuals (Weinshilboum et al., 1973). The interindividual variation of CSF D\( \beta \)H has been found in twin and family studies to be highly heritable in both

---

**Fig. 1.** Structures of the human dopamine transporter gene \( \text{SLC6A3} \), the serotonin transporter gene \( \text{SLC6A4} \), and the norepinephrine transporter gene \( \text{SLC6A2} \) and their relevant variants. A, the human dopamine transporter gene \( \text{SLC6A} \). The exons are represented by black boxes and are numbered. The tall black boxes represent exonic coding regions and the short black boxes represent untranslated exonic regions. B, the serotonin transporter gene \( \text{SLC6A4} \). C, the norepinephrine transporter gene \( \text{SLC6A2} \). All three gene structures were derived from the genomic sequence as presented in the UCSC Genome Browser (http://genome.ucsc.edu/) (July 2003 build) and the GENATLAS (http://www.dsi.univ-paris5.fr/genatlas/).
CSF and plasma (Ross et al., 1973; Weinishilboum et al., 1973; Oxenstierna et al., 1986).

A number of polymorphisms at and near the DβH gene have been linked to variation in DβH levels (Wei et al., 1997a,b; Cubells et al., 1998, 2000; Zabetian et al., 2003). Initially, Wei and colleagues found an association between a short tandem (GT)_{n} dinucleotide repeat located approximately 3000 nucleotides upstream of the DβH locus and plasma DβH in British subjects (Wei et al., 1997a). This association was confirmed in a group of European Americans (Cubells et al., 1998). A polymorphism located approximately 4700 nucleotides upstream from the DβH transcription initiation site (DBH*5′-ins/del, a biallelic 19 nucleotide insertion/deletion) and a synonymous SNP, G444A (DBH*444g/a), which encodes a guanine to adenosine substitution at nucleotide position 444, are in strong linkage disequilibrium and display similar associations to plasma DβH levels (Cubells et al., 1998, 2000). A haplotype analysis of the DBH*5′-ins/del and the G444A (DBH*444g/a) polymorphisms identified an association of the Del-a haplotype with low DβH and also with cocaine-induced paranoia in a group of American Caucasians who abuse cocaine (Cubells et al., 2000). A possibly functional variant, C-1021T (-1021C→T), was associated with plasma DβH activity in European Americans, African Americans, and Japanese (Zabetian et al., 2003). The C-1021T allele was associated with decreased plasma DβH levels in all the populations studied. When DβH activity was compared with this and 11 SNPs across the DβH locus, the C-1021T SNP was associated at the highest significance with DβH activity (Zabetian et al., 2003). Eight nonsynonymous (amino acid-substituting) SNPs have been identified in various populations in the DβH gene: three located in exon 3, G499C (499G→C or Ala197Thr), G589A (589G→A or Ala197Thr), and G675C (675G→T or Lys225Asn); two in exon 4, G706C (706G→C or Glu236Gln) and G826A (826G→A or Asp276Asn); two in exon 5, T908C (908T→C or Leu303Pro) and G910T (901G→T or Ala304Ser); and one in exon 11, C1603T (1603C→T or Arg535Cys) (Halushka et al., 1999; Zabetian et al., 2001). The Ala304Ser variant has been reported to produce altered activity in transient transfection assays (Ishii et al., 1991); however, others have not been able to replicate this finding (Li et al., 1996).

b. Dopamine Receptor D2 Gene (DRD2). Dopamine receptors appear to play a large role in the rewarding effects of drugs of abuse. Somato-dendritic DRD2 receptors on dopaminergic neurons in the ventral tegmental area are activated by dopamine to inhibit the mesolimbic dopaminergic pathway (Di Chiara and Imperato, 1988b; Koob, 1992). In addition, targeted ablation of the DRD2 gene has been shown to remove the rewarding effects of opiates (Maldonado et al., 1997).

A polymorphism of the DRD2 gene, TaqI A, is a non-functional restriction fragment length polymorphism (RFLP) located approximately 10,000 nucleotides downstream of the DRD2 gene and has been repeatedly reported to be associated with, and not associated with, alcoholism (meta-analysis in Noble, 1998) (Hallikainen et al., 2003). The TaqI A RFLP has been associated with heroin use and methadone treatment outcome (Lawford et al., 2003), cocaine dependence (Noble et al., 1993), psychostimulant abuse (Persico et al., 1996), polysubstance abuse (O’Hara et al., 1993), and with early age of onset of multiple substance abuse (Comings et al., 1994). A DRD2 promoter region variant (-141ΔC) was associated with heroin use in Chinese subjects (Li et al., 2002). When this group was subdivided by route of heroin administration, the association of the promoter variant was of greater significance in the inhaler group, whereas significance was not achieved for the injector group. Another RFLP of DRD2, located in intron 2 (TaqI B), also was reported to be significantly associated with polysubstance abuse in Caucasians, but not in African Americans (O’Hara et al., 1993) and in another study with cocaine dependence (Noble et al., 1993).

In a recent analysis of DRD2 binding in caudate nuclei isolated postmortem from Caucasians, the minor alleles at the TaqI A, TaqI B, and an intron 6 variant were significantly associated with lowered B_{max} (40% lower) of the DRD2 receptor (Ritchie and Noble, 2003). In a recent study of six synonymous variants in the DRD2 gene, one of the variants, 957T, was found to cause a decrease in mRNA stability (t_{1/2} 8 h → 4 h) and a 50% decrease in the translational efficiency of the DRD2 mRNA (Duan et al., 2003). This C957T variant altered the predicted DRD2 mRNA folding. Duan and colleagues also found that another naturally occurring variant in DRD2, 1101A, annulled the decrease in mRNA stability conferred by the 957T allele. In addition, it was demonstrated that dopamine stabilized the 957C DRD2 mRNA, whereas there was little stabilization of the 957T DRD2 mRNA. It has been postulated that subjects with reduced DRD2 receptor content may compensate this deficiency through the use of drugs that stimulate the dopaminergic system (Noble, 2000).

c. Dopamine Transporter Gene (SLC6A3). A key regulator of dopaminergic tone is the dopamine transporter, encoded by the gene SLC6A3 (see Fig. 1), which regulates the reuptake of dopamine back into the presynaptic neuron, thereby terminating its action. The dopamine transporter is also the major site of action for cocaine’s pharmacological actions accounting for cocaine’s rewarding properties.

A SNP, G2319A, and a variable number of tandem repeats (VNTR), consisting of a repeat unit of 40 nucleotides, are found in the 3′-untranslated region in exon 15 of the SLC6A3 gene. Subjects with the 9-/10-repeat genotype had a 22% reduction in dopamine transporter availability in the putamen than in subjects homozygous for the 10-repeat allele, as measured by single photon emission computed tomography and plasma radioligand levels, indicating that the VNTR affects expression of
the dopamine transporter (Heinz et al., 2000). However, using the same techniques and radioligand, Jacobson and colleagues found a 13% increase in striatal binding in the 9-10-repeat heterozygotes compared with the 10-repeat homozygotes (Jacobsen et al., 2000b). In an in vitro reporter assay, the 10-repeat allele was found to have a greater transcriptional activity than that for the 7- or 9-repeat alleles (Fuke et al., 2001). However, the dopamine transporter VNTR alleles were not associated with the CSF neurometabolite homovanillic acid, the degradation product of dopamine, in a sample of mostly Swedish Europeans (Jönsson et al., 1998).

In a study by Gelernter and colleagues using a Caucasian sample, no association of this dopamine transporter variant with cocaine dependence was observed (Gelernter et al., 1994). However, they did find an association of the VNTR alleles with cocaine-induced paranoia, indicating a possible alteration in the efficiency of the dopamine transporter to remove dopamine from the synapse. A similar finding was reported by Ujike and colleagues, who showed that the 9- or fewer repeat alleles were associated with methamphetamine psychosis which lasted 1 month or more after discontinuing methamphetamine (Ujike et al., 2003). In addition, in a study of Chinese men, no association of the dopamine transporter VNTR alleles was observed in a study of methamphetamine abuse (Hong et al., 2003).

Two less common allelic variants which alter the coding sequence of the dopamine transporter are the T265C (Val55Ala) in exon 2 that substitutes a valine for an alanine at amino acid 55 in the intracellular N terminus and T1246C (Val382Ala) in exon 8, which substitutes a valine for an alanine at amino acid 382 in the fourth extracellular loop (Vandenbergh et al., 2000). Dopamine uptake velocity and cocaine analog binding were reduced by half with the 1246C (382Ala) allele in transient expression assays, whereas the 265C (55Ala) allele had 1.7-fold lower \( K_m \) for dopamine uptake (Lin and Uhl, 2003).

d. Serotonin Transporter Gene (SLC6A4). The serotonin transporter, encoded by the SLC6A4 gene (see Fig. 1), is expressed on the presynaptic terminals of serotonergic neurons. The serotonin transporter directs the reuptake of serotonin from the synapse into the presynaptic neuron. As was noted above, targeted deletion of the serotonin transporter in mice has shown the involvement of this transporter, along with the dopamine transporter, in cocaine’s mechanism of action.

In single photon emission computed tomography studies with a serotonin transporter ligand, cocaine-dependent subjects had significantly higher serotonin transporter binding sites in the brainstem and diencephalon (Jacobsen et al., 2000a). However, Little and colleagues found, in postmortem brain studies using quantitative autorgraphic and in situ hybridization assays, lowered serotonin transporter binding in cocaine addicts compared with controls in the dorsal raphe, median raphe, and substantia nigra (Little et al., 1998).

The promoter of the serotonin transporter gene contains a GC-rich 44-nucleotide insertion/deletion (5-HTTLPR). This polymorphic site occurs in a repetitive element located approximately 1400 nucleotides upstream from the transcription start site (Lesch et al., 1996). The short variant (s) has been shown in transfection experiments in vivo to have half the transcriptional rate of the long variant (l) (Lesch et al., 1996), and the s variant has an attenuated gene expression response to the synthetic glucocorticoid dexamethasone compared with the l variant (Glatz et al., 2003). Serotonin transporter binding sites and mRNA levels in the dorsal raphe, median raphe, and the substantia nigra of postmortem brain also varied by genotype with the highest level of binding and mRNA in brain regions from subjects with the ll genotype, with lower binding and mRNA levels in the l/s and s/s genotypes (Little et al., 1998).

In a group of Caucasian Italians the serotonin transporter low activity s/s genotype was found to be associated with heroin dependence (Gerra et al., 2004). In addition, the s/s genotype was also associated with aggression within the heroin-dependent group. This serotonin transporter promoter polymorphism was found not to be associated with cocaine dependence in African Americans (Patkar et al., 2001), nor with heroin addiction in the Chinese subjects (Li et al., 2002).

A VNTR is located in the second intron of the serotonin transporter with three alleles: a 9-, 10-, and 12-repeat of a 16–17 nucleotide element. This polymorphism has been shown, in differentiating embryonic stem cells, to possess allele-dependent differential enhancer activity (MacKenzie and Quinn, 1999). In a case-control study of Chinese heroin addicts and controls, an association of the 10-repeat allele with heroin addiction was found (Tan et al., 1999). However, no such association of this serotonin transporter VNTR was observed in a study of cocaine dependence in African Americans (Patkar et al., 2002) or in methamphetamine abuse in Chinese subjects (Hong et al., 2003).

e. Norepinephrine Transporter Gene (SLC6A2). Similar to the other monoamine transporters, the norepinephrine transporter clears its cognate monoamine neurotransmitter, norepinephrine, from synapses in the brain and peripheral nervous system by reuptake into presynaptic neurons. The norepinephrine transporter is the site of action of many of the tricyclic antidepressants (e.g., desipramine). The norepinephrine transporter can transport both norepinephrine and dopamine (Horn, 1973; Raiteri et al., 1977) and has been found to have a higher binding affinity for dopamine than does the dopamine transporter (Giros et al., 1994; Gu et al., 1994; Eshleman et al., 1999). Targeted disruption of SLC6A2 in mice produces an increase in extracellular norepinephrine and a decrease in intracellular norepinephrine in the brain (Xu et al., 2000). Further studies in norepi-
nephrine transporter knockout mice have demonstrated that dopamine uptake in the frontal cortex probably occurs through the action of the norepinephrine transporter (Moron et al., 2002). In these knockout mice, morphine treatment produced greater analgesia than in wild-type mice, indicating that the effect of tricyclic antidepressants, which block reuptake of norepinephrine by binding to the norepinephrine transporter, may function by enhancing the effects of endogenous opioids (Bohn et al., 2000). These knockout mice were hypersensitive to locomotor stimulation by cocaine or amphetamine (Xu et al., 2000).

Screening of the norepinephrine transporter (SLC6A2) gene has identified one promoter variant (T-182C), five nonsynonymous (amino acid altering), and eight synonymous or intronic variants (Stober et al., 1996; 1999). The nonsynonymous coding region variants G205A (Val69Ile), C296T (Thr99Ile), G733A (Val245Ile), G1345A (Val449Ile), and G1432A (Gly478Ser) were all located in transmembrane domains of the norepinephrine transporter in exons 1, 2, 4, 9, and 10, respectively, and in transmembrane domains 1, 2, 4, 9, and 10, respectively. When these five nonsynonymous variants were assayed in cellular constructs, the only difference between these variants and the wild-type norepinephrine transporter was with the G1432A (Gly478Ser) variant (Runkel et al., 2000). This G1432A variant coded for a protein that displayed a 4-fold higher $K_m$ for norepinephrine with no effect on $V_{max}$, indicative of an altered substrate recognition domain. A synonymous variant, A1287G, has been shown to be associated with CSF 3-methoxy-4-hydroxyphenylglycol, a norepinephrine neurometabolite, in Caucasians (Jonsson et al., 1998). Another nonsynonymous variant, C1369G, results in the substitution of an alanine to proline at amino acid 457 in transmembrane domain 9 of the norepinephrine transporter (Shannon et al., 2000; Paczkowski et al., 2002). The 1369C allele, which codes for the 457Pro substituting transporter (Shannon et al., 2000; Paczkowski et al., 2002).

### IV. Treatment of Addictions

#### A. Pharmacotherapies

1. Opiate and Opioid Addictions. Since the original studies of the treatment of heroin addiction with methadone performed at The Rockefeller University by Dole, Nyswander, and Kreek in 1964, significant progress has been made in the understanding of the addictive diseases (Dole et al., 1966). Methadone maintenance treatment has become the standard of treatment for heroin addiction and remains the most efficacious treatment agent in the armamentarium for addictive diseases.

Since these initial studies, two other opioid medications have been approved for use in the treatment of heroin addiction, LAAM and buprenorphine (preferably combined with naloxone). Unlike short-acting injected opiates, each of these medications is long-acting and orally (or, in the case of buprenorphine, sublingually) available thereby reducing their pharmacologically and behaviorally reinforcing properties.

a. Methadone. Methadone is a synthetic opioid with high (>90%) oral bioavailability. Following oral administration, peak plasma levels are achieved by 2 to 4 h and maintained for approximately 24 h (Inturrisi and Verebely, 1972a; Breek, 1973). There is significant cross-tolerance between methadone and other opiates which contribute to its ability to ameliorate withdrawal, reduce craving, and block the euphoric effects of codeinized illicit opiates (Dole et al., 1966). Despite cross-tolerance to other opiates, once steady-state dosing is achieved, little further tolerance to methadone develops (possibly through the modest N-methyl-D-aspartate antagonism provided by both enantiomers of methadone) allowing for stable dosing, typically in the range of 80 to 120 mg per day (Gorman et al., 1997; Davis and Inturrisi, 1999; Callahan et al., 2004).

Following administration, methadone is more than 90% plasma protein bound (primarily by albumin but also by globulins) and slowly released in unmetabolized form from the liver which contributes to its extended period of activity when administered chronically (Kreek et al., 1978). Methadone is N-demethylated in the liver by the cytochrome P450 enzyme family (mostly CYP3A4, but also CYP2D6 and CYP1A2) to inactive metabolites which undergo oxidative metabolism and are excreted in both the urine and the feces (Bowen et al., 1978). Methadone is a full and highly selective MOR agonist. Once steady state is achieved, PET with the $\mu$-preferring opioid antagonist $[^{18}F]$cyclofoxy in stable dose methadone-treated former heroin addicts has revealed that approximately 67 to 81% of MOR in different brain regions are unoccupied by methadone and remain available for their usual physiological roles (Kling et al., 2000).

b. Levo-α-acetylmethadol. LAAM is a methadone congener, which, like methadone, also undergoes N-demethylation through a CYP3A4-mediated microsomal pathway. Unlike the demethylated metabolites of methadone, the metabolites of LAAM, nor-LAAM, and dinorLAAM are pharmacologically active and protein bound, contributing to LAAM’s extended period of activity (up to 96 h) (Sullivan et al., 1973). Like methadone, LAAM also achieves steady-state occupation of MOR, although the extent of this in vivo in humans has not been fully determined. Ten cases of potential adverse cardiac effects attributed to LAAM caused the European Agency for the Evaluation of Medicinal Products to recommend that LAAM be removed from the market throughout the European Union. In February 2004, citing potential
problems related to prolongation of the cardiac QT interval, Roxane, the U.S. marketer of LAAM (brand name Orlaam), ceased LAAM production, although it remains approved by the Food and Drug Administration for the treatment of heroin addiction.

c. Buprenorphine. Buprenorphine is a synthetic opioid with primarily MOR partial agonism and modest κ opioid receptor activity. It is available for heroin detoxification as a single agent but marketed primarily in the United States in a combination preparation with naloxone (to reduce intravenous abuse potential) for maintenance therapy. Buprenorphine has a much shorter terminal half-life (3 to 5 h) than either methadone (24 to 36 h) or LAAM (greater than 48 h) but dissociates slowly from MOR over 24 to 48 h, allowing for daily or even once every 3-day dosing (Nath et al., 1999). Because it is a partial agonist with strong MOR affinity, buprenorphine can induce withdrawal symptoms in moderately to highly opiate tolerant individuals, and it is recommended that buprenorphine not be administered until tolerance is reduced or withdrawal symptoms are apparent. As a partial MOR agonist, buprenorphine reaches a ceiling effect following doses greater than 24 to 32 mg sublingually (Walsh et al., 1994). A PET study using the MOR agonist [11C]carfentanil performed in heroin addicts maintained on varying doses of buprenorphine for 21 to 68 days found that whole brain MOR occupancy is directly related to buprenorphine dose with 41% occupancy following 2 mg and 84% occupancy following 32 mg (Greenwald et al., 2003). Whether this increase in MOR occupancy compared with that seen in methadone maintenance prevents a return to normal physiological function remains uncertain.

Because of extensive first-pass metabolism buprenorphine is administered sublingually. Buprenorphine is dealkylated by CYP3A4 to the metabolite norbuprenorphine, which is also active at MOR (Kobayashi et al., 1998). Intravenously administered buprenorphine can be euphorogenic and cause life-threatening respiratory depression in nonopiate tolerant individuals and is a significant drug of abuse in several countries (Kintz, 2001). By combining buprenorphine with the MOR-prefering antagonist naloxone, the immediate reinforcing euphorogenic effects of intravenously administered buprenorphine can be significantly reduced (Stoller et al., 2001). Naloxone, however, has low oral bioavailability (<3%) and, following sublingual administration of the combination product, does not lead to increased withdrawal symptoms compared with buprenorphine alone (Stoller et al., 2001). When administered as part of a well structured clinical or private medical office setting, opioid agonist therapy with methadone, LAAM, or buprenorphine can have 1-year treatment retention rates greater than 80% (Johnson et al., 2000; Kakko et al., 2003).

d. Naltrexone. In areas where regulatory constraints prevent agonist therapy from being used (e.g., in opioid-addicted physicians in some, but not all, states), opioid antagonist therapy with naltrexone is attempted. Drug-free retention rates are often less than 20%, and this form of management should not be considered a frontline treatment (San et al., 1991; Kakko et al., 2003).

e. Clonidine. Other medications used in the treatment of opiate addiction are the α-2-adrenergic receptor agonists clonidine and lofexidine (the latter not approved for use in the United States). These medications are hypothesized to reduce the action of excess norepinephrine in the locus ceruleus during acute opiate withdrawal; they have been shown to ameliorate some signs and symptoms, such as the increased lacrimation, rhinorrhea, and gastrointestinal distress experienced during acute opiate withdrawal but have little effect on others.

2. Cocaine Addiction.

a. Antidepressants. There are no effective pharma-therapeutics for cocaine addiction (Lima et al., 2002). Tricyclic antidepressants and serotonin reuptake inhibitors have been widely used in the treatment of cocaine addicts but have not been widely efficacious. In some individuals with underlying comorbid psychiatric conditions, these medications may have a slight benefit.

b. Disulfiram. Disulfiram, traditionally used with minimal success in the treatment of alcoholism, has received attention for the treatment of cocaine addiction because of its ability to block the conversion of dopamine to norepinephrine through inhibition of the enzyme DβH (Carroll et al., 1993, 2004; Higgins et al., 1993). This compound is now under study to determine whether it has any general usefulness in the treatment of cocaine addiction.

c. Dopaminergic Agents. Therapeutics such as methylphenidate and other medications (e.g., bromocriptine, pergolide, and amantadine), which act as dopamine agonists, also show limited efficacy in the treatment of cocaine addiction (Khantzian et al., 1984; Grabowski et al., 1997; Handelsman et al., 1997; Malcolm et al., 2000; Shoptaw et al., 2002). The efficacy of methylphenidate, however, may be apparent only in cocaine addicts with comorbid attention deficit/hyperactivity disorder rather than cocaine addicts in general (Gawin et al., 1985; Levin et al., 1998; Schubiner et al., 2002).

d. GABA_A-GABA_B Directed Drugs Indirectly modulating dopamine through agonism of GABAergic neu-rons has also been studied as a means of treating cocaine addiction. Trials using the GABA_B agonist baclofen have shown reductions in cocaine craving, but long-term outcome studies looking at craving and continued cocaine use are needed (Ling et al., 1998; Shoptaw et al., 2003). The GABA analog gabapentin has also been evaluated and has shown modest benefit, although larger placebo-controlled efficacy trials are needed (Myrick et al., 2001).

Although none of the medications for cocaine addiction mentioned above have achieved the success of phar-
macotherapeutics used for heroin addiction, or even pharmacotherapeutics for alcohol addiction, the recent advances in human molecular genetics related to their proposed mechanisms of action make them worthy of discussion and further pharmacogenetic and pharmaco-therapeutic investigation.

V. Pharmacogenetics Related to the Treatment of Addictions

Variants of genes encoding proteins involved in the metabolism or biotransformation of drugs of abuse may affect vulnerability to develop an addiction. A frequently cited example is the SNP encoded dysfunction of aldehyde dehydrogenase (produced by the ALDH2*2 allele variant), an enzyme responsible for the biotransformation of the toxic alcohol metabolite acetaldehyde (Yoshida et al., 1984, 1991). This SNP is present in approximately 40% of Asians and results in a flushing response following alcohol consumption that most people find unpleasant (Harada et al., 1980; Higuchi et al., 1992). Subjects homozygous for the ALDH2*2 allele were less likely to become alcohol dependent than heterozygous subjects who were less likely to be alcohol dependent than subjects with the prototypic gene (Harada et al., 1982; Higuchi et al., 1992, 1996). Variants of genes encoding proteins involved in the metabolism of opiates and cocaine have been identified and may be associated with the vulnerability to develop or affect the treatment of the addictive diseases. Most of the enzymes involved in opiate metabolism are part of the P450 family of microsomal enzymes; however, heroin and morphine also undergo non-P450-mediated biotransformation.

A. Metabolism/Biotransformation of Opiates and Other Opioids

1. Morphine and Heroin. Morphine, a phenanthrene alkaloid, still is derived today (due to the difficulty of synthetic production) from the milky extract of the unripened seed pods of the poppy plant, Papaver somniferum. Morphine comprises approximately 10% of the opium extract from the plant. Diacetylmorphine (heroin) was first synthesized in 1874 and then marketed as heroin in 1898 by Bayer. Heroin is a lipid soluble prodrug that exerts its effect only after metabolism to 6-monoacetylmorphine (6-MAM) and morphine. Heroin has little oral bioavailability and undergoes complete first-pass metabolism with blood clearance greater than the upper limit of hepatic blood flow, indicating additional extrahepatic metabolic factors.

Heroin is metabolized to 6-MAM and then morphine by hydrolysis of ester linkages catalyzed by three esterases: pseudocholinesterase, human carboxylesterase-1 (hCE-1), and human carboxylesterase-2 (hCE-2). In humans, heroin is metabolized by hydrolysis of the 3-acetyl group to 6-MAM in the liver by hCE-1 and hCE-2, in the serum by pseudocholinesterase, and also nonenzymatically in the serum. Whereas all three enzymes catalyze the rapid hydrolysis of heroin to 6-MAM, only hCE-2 catalyzes hydrolysis of 6-MAM to morphine with high efficiency (Kamendulis et al., 1996).

Morphine undergoes glucuronidation by uridine diphosphate glucuronosyltransferases (UDP glucuronosyltransferases) to the inactive metabolite morphine-3-glucuronide (M3G) and, to a lesser extent, the MOR agonist M6G. A recent study of five subjects with Gilbert syndrome, characterized by impaired glucuronidation due to a polymorphism in the gene encoding UDP glucuronosyltransferase (UGT) 1A1, did not show altered morphine clearance or difference in the plasma concentration versus time curves for M6G or M3G compared with controls (Skarke et al., 2003b). A promoter region SNP (C-161T) in the gene encoding UGT 2B7 (UGT2B7) has been identified in individuals with low rates of glucuronidation, and subjects with this SNP show reduced M6G/morphine ratios; since this SNP was complete linkage disequilibrium with the nonsynonymous C802T SNP (His268Tyr) in exon 2, it is unclear which of these two SNPs is the functional variant (Sawyer et al., 2003). Other studies have also identified promoter or coding region polymorphisms of UGT2B7, however, none significantly alter morphine clearance or M6G and M3G formation and clearance (Holthe et al., 2002, 2003; Duguay et al., 2004). Further studies to identify functional polymorphisms and their effect on morphine metabolism are needed to determine whether there are physio- or pharmacogenetic factors contributing to morphine addiction and/or analgesia.

2. Codeine. Most opiates (other than heroin and morphine) are metabolized by P450 enzymes. While a portion of codeine undergoes glucuronidation, it is also O-demethylated (as are its congeners oxycodone and hydrocodone) to the active and more potent metabolite morphine (oxymorphone and hydromorphone for oxycodone and hydrocodone, respectively) by CYP2D6. Over 60 variants (including gene duplications, gene deletions, alternative splicing, insertions and deletions with changes in the reading frame, and SNPs imparting amino acid substitutions) of the CYP2D6 gene have been identified (for a review, see Howard et al., 2002). Some of these variants increase metabolism of these drugs into their more potent metabolites, whereas others decrease metabolism. The analgesic potency and abuse liability of opioid medications may, therefore, be influenced by variants in this gene (Sindrup et al., 1991, 1993; Kathiramalanathan et al., 2000). Tyndale et al. (1997) reported that no subjects meeting DSM-IV criteria for oral opioid dependence had either of the defective mutant alleles CYP2D6*3 or CYP2D6*4 which reduce metabolism compared with control and multidrug-dependent individuals whose frequency for these alleles did not differ from that of previously reported Caucasian control populations. Pharmacological inhibition of CYP2D6 with fluoxetine or quinidine, which significantly reduces the formation
of morphine following codeine administration (Kathiramalainathan et al., 2000; Romach et al., 2000), however, failed to reduce daily codeine intake in a small cohort of codeine addicts (Fernandes et al., 2002). The effect of CYP2D6 alleles resulting in low versus ultrarapid metabolism has been investigated in methadone-maintained subjects. Although the metabolism of methadone is primarily mediated by CYP3A4, the investigators did find a significant decrease in dose-to-weight corrected methadone concentrations in the ultrarapid metabolizers, but this did not appear to influence treatment outcome compared with the low metabolizer group (Eap et al., 2001).

3. Methadone, Levo-a-acetylmethadone, and Buprenorphine. The standard medications used in the treatment of opiate addiction, methadone, LAAM, and buprenorphine, are all primarily metabolized by CYP3A4. Concomitant use of medications that induce (e.g., rifampin, phenytoin) or inhibit (e.g., fluoxetine, cimetidine, saquinavir) CYP3A4 may result in withdrawal symptoms or sedation, respectively. Polymorphisms that affect CYP3A4 function may similarly influence the efficacy of these treatment agents. Over 20 variants of CYP3A4 have been identified (http://www.imm.ki.se/CYPalleles/cyp3a4.htm), and two studies using cellular constructs have identified variants that increase or decrease CYP3A4 function and alter testosterone (a CYP3A4 substrate) metabolism (Dai et al., 2001; Eiselt et al., 2001). The functional effects of other CYP3A4 variants have not been determined and there are no reports on whether CYP3A4 variants alter the metabolism of medications used in the treatment of the addictive diseases.

B. Metabolism/Biotransformation of Cocaine

Cocaine is a tropane ester alkaloid extracted from the leaves of the coca bush, Erythroxylon coca, which grows in the Andean region of South America. Similar to heroin, cocaine metabolism is catalyzed by pseudocholinesterase, hCE-1, and hCE-2. Hydrolysis of cocaine to ecgonine methyl ester is catalyzed by pseudocholinesterase and hCE-2. Ecgonine methyl ester is then nonenzymatically hydrolyzed. hCE-1 catalyzes transesterification of cocaine to cocaethylene, a toxic metabolite, in the presence of ethanol and also hydrolysis to benzoylecgonine, the primary metabolite excreted in the urine. Cocaethylene can be further hydrolyzed by hCE-1 or hCE-2, producing benzoylecgonine or ecgonine ethyl ester, respectively (Dean et al., 1991; Brzezinski et al., 1994; Laizure et al., 2000).

Phenotypic variation in pseudocholinesterase is associated with prolonged apnea in patients receiving the muscle relaxant drug succinylcholine during surgery. The dibucaine number, a method for measuring activity of pseudocholinesterase, has for many years been used to identify atypical phenotypes of this enzyme that display decreased or even complete absence of activity (Kalow and Genest, 1957; Kalow and Staron, 1957). Several genetic variants have been identified that are responsible for some of these phenotypic abnormalities (e.g., McGuire et al., 1989; Nogueira et al., 1990a,b; Maekawa et al., 1997). An earlier investigation of serum from a person identified as having an inactive phenotype of this enzyme revealed that it did not hydrolyze heroin, and serum from a patient with an atypical, partially active, phenotype hydrolyzed heroin but with less efficiency than the typical enzyme (Lockridge et al., 1980). More recently, the activity of several human cholinesterase variants with cocaine has been examined (Xie et al., 1999). One atypical cholinesterase (Asp70Gly) had 10-fold lower binding efficiency for cocaine and 10-fold lower catalytic efficiency (k_{cat}/K_m). Although this evidence suggests the possibility that individual responses to heroin and cocaine may be mediated in part by greater or lesser metabolic capacity, genetically determined variations in cholinesterase activity, or in activity of the carboxylesterase (referred to above), have not been investigated in persons with addictive diseases.

VI. Summary

Herein we have reviewed a number of genes that appear to be involved in the vulnerability to and the treatment of heroin and/or cocaine addiction. The evidence for the roles of a few of these genes and the influence of their variants in these diseases remain tenuous and will require replication, whereas the roles of others appear to be fairly well established. It must be remembered that association or linkage results may not directly identify a functional polymorphism, but may only indicate that a functional polymorphism is in linkage disequilibrium. Functional variants may alter the primary structure of the resultant protein, modify the transcriptional profile of the gene, alter splicing or stability of the mRNA, or alter translational efficiency. Furthermore, some alleles may only exert an effect in the context of other alleles within the same gene or of other genes.

To further elucidate the genetic variability that may contribute to the vulnerability, acquisition, and treatment of cocaine and/or heroin addiction, studies will be required to identify both new alleles as well as to confirm the role of previously identified alleles. If the diseases of addiction are to be understood, treated, and prevented, these studies will be necessary and invaluable. However, genetics are only one aspect that contributes to the development of heroin or cocaine addiction. Environmental factors are also of importance. To further our knowledge into the physiology of these addictions, the interplay of genes with environmental factors will have to be evaluated to a greater extent. Exposure to heroin or cocaine are necessary factors. Investigations will have to take into account how specific genes and their specific alleles interact with each other and with
the environment. New analysis techniques such as haplotype analyses should aid in attaining these goals. To develop novel pharmacotherapies as well as behavioral therapies and to create new prevention and treatment programs, the roles of genes, their variants, and the environment in which they are expressed will have to be elucidated.

Acknowledgments. We thank Susan Russo for assistance in preparation of the manuscript. Funding support was received from the National Institutes of Health (NIH) National Institute on Drug Abuse Scientific Award Grant K05-DA000049, the National Institutes of Health-National Institute on Drug Abuse Research Center Grant P60-DA05130, the National Institutes of Health-National Institute on Drug Abuse Research Grant R01-DA09444, the National Institutes of Health-National Institute on Drug Abuse Research Center Grant R01-DA12845, the National Institutes of Health-National Center for Research Resources (NCRR) General Clinical Research Center Grant M01-RR01002, and the New York State Office of Alcoholism and Substance Abuse Services.

References


